PARIS & LAUSANNE, Switzerland--(BUSINESS WIRE)--Regulatory News: Galderma, the leading pharmaceutical company in dermatology, and Ipsen (Paris:IPN), an international innovation-driven specialty pharmaceutical group, today announced that Azzalure® (botulinum toxin Type A manufactured by Ipsen), a muscle relaxant specifically developed for aesthetic use, has received a marketing authorization in Germany from the regulatory authorities (Bundesinstitut für Arzneimittel und Medizinprodukte) for the temporary improvement in the appearance of moderate to severe glabellar lines seen at the frown (vertical lines between the eyebrows), in adult men and women aged 65 years and under, when the severity of these lines has an important psychological impact on the patient.
